Law360, New York (August 11, 2009) -- The direct purchaser plaintiffs in an antitrust class action alleging that Biovail Corp. and GlaxoSmithKline PLC conspired to stifle the market for a generic version of antidepressant Wellbutrin XL have charged ahead with their battle to have a set of documents related to several underlying patent cases released for discovery.
The group filed a memorandum of law Monday in the U.S. District Court for the Eastern District of Pennsylvania in support of an earlier motion to compel discovery, asking the...
